Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
Published Date: 17 Mar 2023
Bladder cancer is not a rare disease. It is one of the 10 most common cancers in the UK and the 5th most common cancer in the European Union.
Read Full NewsThree medical societies claim recent studies have overestimated the potential harms from lung cancer screening and may be deterring patients. Not everyone agrees.
Despite FDA package insert recommendations, most patients with breast cancer who are prescribed CDK4/6 inhibitors do not receive liver function tests before starting treatment.
Patients who receive both standard medical treatment and complementary and alternative therapies have higher mortality — possibly due to reduced use of endocrine therapy and radiation.
1.
Beyond What Is Visible in Myelofibrosis?
2.
Gene therapy for glioblastoma is effectively created by researchers.
3.
Except for Black Patients, the Rates of Gallbladder Cancer Are Stable or Declining.
4.
Survival rates for incurable larynx cancer investigated for first time
5.
Rural-urban disparities seen in cervical cancer
1.
Understanding Granulosa Cell Tumors: Symptoms, Diagnosis, and Treatments"
2.
Understanding Carcinoid Tumors: Diagnosis, Symptoms, and Treatment Options
3.
Breaking Down the Different Types of Lymphoma: What You Need to Know
4.
The Miracle of Tenecteplase: How This Drug Is Saving Lives
5.
Understanding Neutrophilia: Causes, Symptoms, and Treatment Options
1.
International Lung Cancer Congress®
2.
Future NRG Oncology Meeting
3.
Genito-Urinary Oncology Summit 2026
4.
ISMB 2026 (Intelligent Systems for Molecular Biology)
5.
Annual International Congress on the Future of Breast Cancer East
1.
Updates on Standard V/S High Risk Myeloma Treatment- The Next Part
2.
Recent Data Analysis for First-Line Treatment of ALK+ NSCLC: A Final Discussion
3.
Role of Nimotuzumab in Management of Nasopharyngeal Cancer
4.
ESMO Breast Cancer 2022: P Reality X- A Restrospective Analysis
5.
Newer Immunotherapies for Myeloma- A Comprehensive Overview- Part II
Address :
Hidoc Dr. Inc. | Delaware C Corp | 1309 Coffeen Ave. Suite 1200, Sheridan WY, 82801
Phone :
+1-415-463-3094
Email :
anishagadia@hidoc.co
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
To get started please enter your email ID
Join to enhance your clinical skills and gain specialized in-depth medical knowledge